NASDAQ:ADXS - Advaxis Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.66
▼ -0.0163 (-2.40%)
1 month | 3 months | 12 months
Get New Advaxis Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADXS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADXS

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Advaxis in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.66.
N/A
The current consensus among 0 polled investment analysts is to n/a stock in Advaxis. This rating has held steady since June 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/15/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/14/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/13/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/11/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/12/2019HC WainwrightReiterated RatingHold ➝ NeutralLow
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/5/2019HC WainwrightSet Price TargetHold$4.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
1/16/2019HC WainwrightReiterated RatingHoldHigh
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/18/2018HC WainwrightDowngradeBuy ➝ NeutralHigh
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/6/2018HC WainwrightSet Price TargetBuy$2.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
9/12/2018HC WainwrightReiterated RatingBuyMedium
i
Rating by Swayampakula Ramakanth at HC Wainwright
6/13/2018Jefferies Financial GroupDowngradeBuy ➝ Hold$9.00 ➝ $2.00High
i
6/8/2018HC WainwrightReiterated RatingBuy$3.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
4/17/2018HC WainwrightReiterated RatingBuy$6.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/14/2018HC WainwrightSet Price TargetBuy ➝ Buy$23.00 ➝ $6.00High
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/13/2018Cantor FitzgeraldLower Price TargetHold ➝ Overweight$19.00 ➝ $5.00High
i
Rating by Mara Goldstein at Cantor Fitzgerald
12/28/2017Cantor FitzgeraldSet Price TargetBuy$19.00Low
i
Rating by Mara Goldstein at Cantor Fitzgerald
12/27/2017HC WainwrightSet Price TargetBuy$23.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
12/22/2017Cantor FitzgeraldSet Price TargetBuy$19.00Low
i
Rating by Mara Goldstein at Cantor Fitzgerald
11/8/2017HC WainwrightReiterated RatingBuy$23.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
9/25/2017Cantor FitzgeraldReiterated RatingBuy$19.00High
i
Rating by Mara Goldstein at Cantor Fitzgerald
9/15/2017HC WainwrightReiterated RatingBuy$23.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
7/6/2017Cantor FitzgeraldSet Price TargetBuy$19.00Low
i
Rating by Mara Goldstein at Cantor Fitzgerald
6/14/2017HC WainwrightSet Price TargetBuy$23.00Medium
i
Rating by Swayampakula Ramakanth at HC Wainwright
6/12/2017Cantor FitzgeraldSet Price TargetBuy$19.00Medium
i
Rating by Mara Goldstein at Cantor Fitzgerald
5/31/2017Cantor FitzgeraldReiterated RatingOverweight$19.00Medium
i
Rating by Mara Goldstein at Cantor Fitzgerald
3/13/2017HC WainwrightSet Price TargetBuy$23.00Low
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/1/2017HC WainwrightReiterated RatingBuy$23.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
2/27/2017Cantor FitzgeraldReiterated RatingBuy$19.00N/A
i
1/17/2017HC WainwrightSet Price TargetBuy$23.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
11/29/2016Cantor FitzgeraldInitiated CoverageBuy$19.00N/A
i
10/25/2016HC WainwrightSet Price TargetBuy$23.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
9/9/2016Jefferies Financial GroupReiterated RatingBuy$24.00N/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
8/25/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
8/5/2016HC WainwrightReiterated RatingBuy$23.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
8/4/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
8/3/2016BarclaysBoost Price TargetOverweight$15.00 ➝ $20.00N/A
i
7/7/2016(FBRC)Reiterated RatingOutperform$34.00N/A
i
Rating by Vernon Bernardino at (FBRC)
6/29/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
6/10/2016Jefferies Financial GroupReiterated RatingBuyN/A
i
Rating by Biren Amin at Jefferies Financial Group Inc.
6/9/2016HC WainwrightReiterated RatingBuy$23.00N/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
5/17/2016(FBRC)Reiterated RatingOutperform$34.00N/A
i
Rating by Vernon Bernardino at (FBRC)
4/21/2016HC WainwrightReiterated RatingBuyN/A
i
Rating by Swayampakula Ramakanth at HC Wainwright
3/29/2016(FBRC)Reiterated RatingOutperform ➝ Positive$34.00N/A
i
Rating by Vernon Bernardino at (FBRC)
3/9/2016(FBRC)Reiterated RatingOutperformN/A
i
Rating by Vernon Bernardino at (FBRC)
(Data available from 3/8/2016 forward)
Advaxis logo
Advaxis, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of proprietary Listeria monocytogenes (Lm) technology antigen delivery products in the United States. The company is developing ADXS-PSA, which is in Phase 2 clinical trials for the treatment of metastatic prostate cancer; ADXS-503 that is in Phase 1/2 clinical trials for the treatment of non-small cell lung cancer; and ADXS-504 for the treatment of prostate cancer. It is also conducting clinical studies of Lm Technology immunotherapies in the following areas of disease focused hotspot/off-the-shelf neoantigen-directed therapies; human papilloma virus-associated cancers; and prostate cancer. The company has collaborations and partnerships with Merck & Co., Inc.; OS Therapies, LLC; Aratana Therapeutics Inc.; Biocon Limited; Global BioPharma Inc.; Knight Therapeutics Inc; and others. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Read More

Today's Range

Now: $0.66
$0.66
$0.73

50 Day Range

MA: $0.89
$0.61
$1.41

52 Week Range

Now: $0.66
$0.26
$1.57

Volume

64,991 shs

Average Volume

16,521,768 shs

Market Capitalization

$74.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.18

Frequently Asked Questions

What sell-side analysts currently cover shares of Advaxis?

The following equities research analysts have issued stock ratings on Advaxis in the last twelve months:
View the latest analyst ratings for ADXS.

What is the current price target for Advaxis?

0 Wall Street analysts have set twelve-month price targets for Advaxis in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Advaxis in the next year.
View the latest price targets for ADXS.

What is the current consensus analyst rating for Advaxis?

Advaxis currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for ADXS.

What other companies compete with Advaxis?

How do I contact Advaxis' investor relations team?

Advaxis' physical mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company's listed phone number is 609-452-9813 and its investor relations email address is [email protected] The official website for Advaxis is www.advaxis.com.